# Demiurge Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/demiurge-technologies

- Industry: Pharmaceuticals
- Headquarters: Zug, Switzerland
- Website: www.demiurge.technology
- Total disclosed funding: $7.7M
- Latest round: Series A (Nov 1, 2015)
- Investors on record: 1

## About

Demiurge Technologies AG develops advanced virtual patient models to enhance clinical trial predictions, focusing on therapeutic areas such as oncology, cardiovascular, and infectious diseases.Founded in 2015 and headquartered in Zug, Switzerland, Demiurge Technologies AG specializes in creating virtual patient models that predict clinical trial outcomes. The company has completed 2 deals, with the most recent funding round occurring on November 1, 2015. During this Series A funding, Demiurge raised USD 7.7 mn from Hongdao Capital, totaling USD 7.7 mn raised to date. The company is led by CEO Idonae Lovetrue.Demiurge Technologies specializes in the development of virtual patient models designed to predict clinical trial outcomes across various therapeutic areas, including oncology, cardiovascular, and infectious diseases. Their core product offerings include advanced predictive modeling for phase 2 and phase 3 clinical trials, which utilize a database of clinical data to construct virtual patients that are clinically equivalent to human subjects. The company released a COVID-19 virtual patient model just six weeks following the World Health Organization's confirmation of human-to-human transmission of SARS-CoV-2. Demiurge serves biotech and pharmaceutical companies globally, providing critical insights that enhance decision-making and reduce clinical development timeframes.Demiurge Technologies generates revenue through partnerships with pharmaceutical and biotech companies, leveraging their predictive modeling capabilities in a B2B transaction structure. Clients engage with Demiurge to utilize their virtual patient models, which facilitate data-driven decision-making in clinical trials. The company’s flagship service is the provision of predictions for clinical trial outcomes, optimizing client investment and research efforts. Pricing plans are not disclosed, but the transactional model likely involves fees based on service complexity and scale, potentially tied to subscription agreements or project-based contracts.Demiurge Technologies plans to enhance its offerings by designing new virtual patient models for emerging therapeutic areas. Additionally, the company aims to expand its geographic presence, targeting markets in North America and Europe by 2026. Recent Series A funding will support these initiatives, providing the necessary resources for product development and market entry strategies.

## Funding rounds

- Series A, Nov 1, 2015, $7.7M — Hongdao Capital

## Investors

- Hongdao Capital (https://capitalatlas.ai/funds/hongdao-capital) — Series A